{"id":"NCT00548860","sponsor":"American Regent, Inc.","briefTitle":"Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients","officialTitle":"A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-03","completion":"2009-07","firstPosted":"2007-10-24","resultsPosted":"2015-05-29","lastUpdate":"2018-02-20"},"enrollment":2018,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose","otherNames":[]},{"type":"DRUG","name":"Standard Medical Care (SMC)","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Standard Medical Care (SMC)","type":"ACTIVE_COMPARATOR"}],"summary":"The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.","primaryOutcome":{"measure":"Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.","timeFrame":"From Day 0 through 30 days after the last dose of study drug.","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":6,"sd":null},{"arm":"Standard Medical Care (SMC)","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["28487769"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":996},"commonTop":["Constipation"]}}